Peptide legal status by region: US, UK, EU and Australia

Peptide legality is region-specific and moving. This is a high-level orientation, not legal advice, and it can go out of date quickly. Always verify the current status of a specific peptide in your own country before relying on anything here.

The broad picture

• United States: research-use framing is more tolerated, and reclassification has been loosening access for some peptides.
• United Kingdom: the MHRA enforces against medicinal claims and human-use sale; keep to educational content.
• European Union: member-state variation, with some countries (e.g. Germany) stricter than others.
• Australia: the strictest — most peptides are Schedule 4 (prescription-only) and melanotan II is Schedule 9 (prohibited).

What Aminove does about it

Aminove shows a legal flag per peptide and per region in the library, and applies a more conservative content posture in stricter regions — including withholding community-reported ranges where appropriate. You set your region during onboarding.

This is not legal advice. Regulatory status changes; obtain local, current guidance before acting.